Axa
BCYC

Axa’s Bicycle Therapeutics BCYC Stock Holding History

Axa’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-280,152
Closed -$1.95M – 182
2025
Q2 		$1.95M Sell
280,152
-273,530
-49% -$2.18M 0.01% 775
2025
Q1 		$4.7M Sell
553,682
-277
-0.1% -$3.26K 0.02% 560
2024
Q4 		$7.76M Sell
553,959
-440
-0.1% -$9.43K 0.02% 432
2024
Q3 		$12.5M Buy
554,399
+79
+0% +$1.82K 0.04% 360
2024
Q2 		$11.2M Buy
554,320
+157
+0% +$3.55K 0.03% 376
2024
Q1 		$13.8M Buy
554,163
+77
+0% +$1.64K 0.04% 341
2023
Q4 		$10M Sell
554,086
-20,981
-4% -$347K 0.03% 392
2023
Q3 		$11.6M Buy
575,067
+21,435
+4% +$490K 0.04% 365
2023
Q2 		$14.1M Buy
553,632
+93,507
+20% +$2.17M 0.05% 345
2023
Q1 		$9.79M Buy
460,125
+79,570
+21% +$2M 0.03% 418
2022
Q4 		$11.3M Sell
380,555
-30,085
-7% -$807K 0.04% 416
2022
Q3 		$9.55M Sell
410,640
-52,387
-11% -$1.25M 0.04% 440
2022
Q2 		$7.77M Buy
463,027
+317,773
+219% +$6.7M 0.03% 478
2022
Q1 		$6.37M Buy
145,254
+2
+0% +$93 0.02% 582
2021
Q4 		$8.84M Sell
145,252
-53,421
-27% -$2.95M 0.02% 531
2021
Q3 		$8.26M Buy
198,673
+1,163
+0.6% +$40.7K 0.02% 547
2021
Q2 		$6M Sell
197,510
-289
-0.1% -$8.73K 0.02% 657
2021
Q1 		$5.91M Buy
197,799
+52,802
+36% +$1.36M 0.02% 666
2020
Q4 		$2.6M Buy
+144,997
New +$2.8M 0.01% 810

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Axa's BCYC Position: Q3 2025 in Review

Axa sold out of Bicycle Therapeutics (BCYC) in Q3 2025, closing a stake of 280,152 shares — an estimated $1.95M sold.

Axa first reported a position in BCYC in Q4 2020 and held it in 19 quarters. The position peaked at $14.1M in Q2 2023. 99 funds tracked by Wall St. Rank hold BCYC as of Q3 2025.

  • Axa reported no remaining Bicycle Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 280,152 Bicycle Therapeutics shares in Q3 2025, an estimated $1.95M.
  • Axa first reported a position in Bicycle Therapeutics in Q4 2020 and held it in 19 quarters.
  • Axa's Bicycle Therapeutics position peaked at $14.1M in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.